Clinical trials
Systemic Juvenile Idiopathic Arthritis (sJIA) clinical trials
Below are recruiting systemic juvenile idiopathic arthritis (sjia) clinical trials, each written for real people, not researchers. We’re tracking 10 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07845942Recruiting
Donor stem cell transplant for stubborn systemic juvenile arthritis
This study tests a bone marrow transplant (using donor cells) to treat severe systemic juvenile idiopathic arthritis (sJIA) that has not responded to other treatments. The goal is to reset the immune system to stop the disease and its complications, like lung problems or recurrent macrophage activation syndrome.
Cincinnati, OhioAges Up to 35 years - NCT06560606Recruiting
Personalized medicine for childhood arthritis
This study creates a personalized medicine network to better understand and treat childhood arthritis. If you have JIA or unexplained joint inflammation, researchers will look at your biology to find the best treatment approach for you.
Calgary, AlbertaAges Up to 18 years - NCT07517575RecruitingPhase 2
Olokizumab for Children with Juvenile Idiopathic Arthritis
This trial tests a new medicine called olokizumab in children and teenagers with juvenile idiopathic arthritis (JIA)—a condition where the immune system causes joint inflammation and pain. The study checks if this drug is safe and effective for children whose arthritis hasn't improved enough with standard treatments.
Kazan'Ages 2–17 - NCT07517250Recruiting
Study of Canakinumab for Fever and Joint Disease
This is a study looking back at patients who were already treated with a medicine called canakinumab for familial Mediterranean fever or Still's disease (rare conditions that cause fevers and joint pain). Researchers want to understand how well this medicine worked over time and what happened to patients who took it.
BaselAges 1 year+ - NCT06838143Recruiting
Ilaris real-world study for periodic fevers and sJIA
This study watches how people with certain periodic fever syndromes or a severe type of childhood arthritis (sJIA) do on the medicine Ilaris during their regular doctor visits. It collects information to see how well the medicine works in everyday care.
SeoulAges 2–100 - NCT05925452Recruiting
Genalumab for children with active systemic juvenile arthritis
This trial studies whether a medicine called genalumab can reduce inflammation and improve symptoms in children with active systemic juvenile idiopathic arthritis (sJIA). It also checks how safe the treatment is, including possible side effects.
Beijing, BenjingAges 2–17 - NCT05609630RecruitingPhase 3
Testing two medicines for active systemic juvenile arthritis
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
Phoenix, ArizonaAges 1–17 - NCT01962415RecruitingPhase 2
Reduced-intensity stem cell transplant for non-cancer disorders
This trial tests whether a gentler (reduced-intensity) conditioning treatment before a stem cell transplant works for non-cancer diseases. It uses specific donor stem cell matches and checks heart, lung, liver, and kidney function to help lower transplant stress while still aiming for benefit.
Pittsburgh, PennsylvaniaAges 2 months–55 years - NCT03510442Recruiting
Study of genetics and causes of systemic juvenile arthritis and Still's disease
This study aims to learn more about the causes and genetics of two related inflammatory conditions: systemic juvenile idiopathic arthritis (sJIA) in children and adult-onset Still's disease (AOSD) in adults. By studying patients and healthy volunteers, researchers hope to understand these diseases better and find better ways to treat them.
Bethesda, MarylandAges 1 day–100 years - NCT02991469RecruitingPhase 2
Testing sarilumab for children with systemic juvenile arthritis
This trial studies sarilumab, a targeted medicine, to help reduce symptoms in children and teens with systemic juvenile idiopathic arthritis (sJIA) who have not responded enough to current treatments. You may be considered because the study looks at how well and safely repeated doses work in pediatric patients.
San Miguel de Tucumán, Tucumán ProvinceAges 1–17
Hear when a new Systemic Juvenile Idiopathic Arthritis (sJIA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for systemic juvenile idiopathic arthritis (sjia)?
- Yes. Clin2 currently lists 10 recruiting systemic juvenile idiopathic arthritis (sjia) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic juvenile idiopathic arthritis (sjia) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic juvenile idiopathic arthritis (sjia) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.